PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30536265-7	2020	Plasma monocyte chemotactic protein-1 (MCP-1) levels were higher in HFD than NCD, and tended to be lower in HFD+EPA than HFD.	Eicosapentaenoic Acid	112-115	chemokine (C-C motif) ligand 2	Mus musculus	7-37	
30536265-7	2020	Plasma monocyte chemotactic protein-1 (MCP-1) levels were higher in HFD than NCD, and tended to be lower in HFD+EPA than HFD.	Eicosapentaenoic Acid	112-115	chemokine (C-C motif) ligand 2	Mus musculus	39-44	
25925976-9	2015	EPA administration and DHA administration significantly decreased the expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, transforming growth factor-beta, matrix metalloproteinases (MMP)-2, MMP-9, and vascular cell adhesion molecule-1 in the aortas.	Eicosapentaenoic Acid	0-3	chemokine (C-C motif) ligand 2	Mus musculus	113-147	
32331514-8	2020	In in vitro experiments using RAW264.7 cells, pre-treatment of EPA partially suppressed lipopolysaccharide-induced activation of nuclear factor-kappa B and also the transcriptional induction of monocyte chemoattractant protein 1 (MCP-1), a major chemoattractant for macrophages to accumulate in lesions.	Eicosapentaenoic Acid	63-66	chemokine (C-C motif) ligand 2	Mus musculus	194-228	
32331514-8	2020	In in vitro experiments using RAW264.7 cells, pre-treatment of EPA partially suppressed lipopolysaccharide-induced activation of nuclear factor-kappa B and also the transcriptional induction of monocyte chemoattractant protein 1 (MCP-1), a major chemoattractant for macrophages to accumulate in lesions.	Eicosapentaenoic Acid	63-66	chemokine (C-C motif) ligand 2	Mus musculus	230-235	
32331514-10	2020	Consistently, EPA remarkably suppressed MCP-1 expression in lesions, suggesting the in vivo relevance of in vitro studies.	Eicosapentaenoic Acid	14-17	chemokine (C-C motif) ligand 2	Mus musculus	40-45	
17724224-8	2007	The mRNA expression and protein levels of ICAM-1, MCP-1, VEGF, and IL-6 after CNV induction were significantly reduced in EPA-supplemented mice.	Eicosapentaenoic Acid	122-125	chemokine (C-C motif) ligand 2	Mus musculus	50-55	
21367920-9	2011	DHA and EPA decreased TNF-alpha-stimulated MCP-1 mRNA expression by decreasing transcription of the MCP-1 gene.	Eicosapentaenoic Acid	8-11	chemokine (C-C motif) ligand 2	Mus musculus	43-48	
21367920-9	2011	DHA and EPA decreased TNF-alpha-stimulated MCP-1 mRNA expression by decreasing transcription of the MCP-1 gene.	Eicosapentaenoic Acid	8-11	chemokine (C-C motif) ligand 2	Mus musculus	100-105	
21367920-10	2011	DHA and EPA decreased p-ERK expression and nuclear translocation of NF-kappaB, both of which are necessary for TNF-alpha-stimulated MCP-1 expression.	Eicosapentaenoic Acid	8-11	chemokine (C-C motif) ligand 2	Mus musculus	132-137	
21367920-11	2011	Both NF-kappaB and AP-1 sites were involved in transcriptional regulation of the MCP-1 gene by DHA and EPA.	Eicosapentaenoic Acid	103-106	chemokine (C-C motif) ligand 2	Mus musculus	81-86	
21367920-12	2011	We conclude that DHA and EPA inhibit TNF-alpha-stimulated transcription of the MCP-1 gene through interaction of signaling pathways involving ERK and NF-kappaB.	Eicosapentaenoic Acid	25-28	chemokine (C-C motif) ligand 2	Mus musculus	79-84	
20664801-7	2010	In addition, EPA significantly reduced the protein levels of MCP-1 and IL-6 in the retina and the RPE-choroid complex.	Eicosapentaenoic Acid	13-16	chemokine (C-C motif) ligand 2	Mus musculus	61-66	
17724224-9	2007	In vitro, EPA application led to significant inhibition of mRNA and protein levels of ICAM-1 and MCP-1 in endothelial cells and VEGF and IL-6 in macrophages.	Eicosapentaenoic Acid	10-13	chemokine (C-C motif) ligand 2	Mus musculus	97-102	
16282336-10	2006	EPA and specific inhibitors of ERK1/2, JNK and PI3K decreased levels of MCP-1 in MMCs.	Eicosapentaenoic Acid	0-3	chemokine (C-C motif) ligand 2	Mus musculus	72-77	
16282336-0	2006	Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.	Eicosapentaenoic Acid	0-21	chemokine (C-C motif) ligand 2	Mus musculus	103-108	
16282336-8	2006	RESULTS: EPA decreased the levels of serum triglycerides, leptin, urinary albumin and MCP-1, and improved glucose intolerance, mesangial matrix accumulation and tubulointerstitial fibrosis in KKAy/Ta mice.	Eicosapentaenoic Acid	9-12	chemokine (C-C motif) ligand 2	Mus musculus	86-91	
16282336-9	2006	Immunohistochemical staining of MCP-1 and F4/80 in the glomeruli and tubulointerstitial regions was decreased in the EPA-treated group.	Eicosapentaenoic Acid	117-120	chemokine (C-C motif) ligand 2	Mus musculus	32-37	
33812168-6	2021	RESULTS: EPA supplementation reduced expression of C-C motif chemokine ligand 2 (CCL2) by 25% compared to placebo (p = 0.03).	Eicosapentaenoic Acid	9-12	chemokine (C-C motif) ligand 2	Mus musculus	51-79	
33812168-6	2021	RESULTS: EPA supplementation reduced expression of C-C motif chemokine ligand 2 (CCL2) by 25% compared to placebo (p = 0.03).	Eicosapentaenoic Acid	9-12	chemokine (C-C motif) ligand 2	Mus musculus	81-85	
33812168-8	2021	Significant inverse correlations were observed between EPA levels and vascular expression of VCAM1 (r = -0.56, p = 0.001) and CCL2 (r = -0.56, p = 0.001).	Eicosapentaenoic Acid	55-58	chemokine (C-C motif) ligand 2	Mus musculus	126-130